9,225 results match your criteria Gastrointestinal Stromal Tumors


Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series.

J Surg Oncol 2020 Jun 2. Epub 2020 Jun 2.

Department of Academic Surgery, Sarcoma, Melanoma and Rare Tumours Unit, The Royal Marsden Hospital, London, UK.

Background And Objectives: The aim of surgical treatment of gastrointestinal stromal tumors (GIST) is a microscopically complete resection. Initial indications for laparoscopic surgery were limited to smaller tumors, in favorable locations. Over time, indications for minimal invasive surgery (MIS) have expanded, however concerns remain when considering resection of larger GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.26053DOI Listing

Thermal ablation versus hepatic resection for the treatment of liver metastases from gastrointestinal stromal tumors: a retrospective study.

Int J Hyperthermia 2020 ;37(1):592-599

Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

The study aimed to compare effectiveness and safety of thermal ablation and hepatic resection in patients with liver metastases of gastrointestinal stromal tumors (GISTs). A total of 55 patients (27 in the ablation group and 28 in the surgery group) with liver metastases were included. Overall survival (OS) and progression-free survival (PFS) were assessed with Kaplan-Meier's survival estimate curves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02656736.2020.1772513DOI Listing
January 2020

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

JAMA Oncol 2020 May 29. Epub 2020 May 29.

Helios Klinikum Berlin-Buch, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany.

Importance: Adjuvant imatinib is associated with improved recurrence-free survival (RFS) when administered after surgery to patients with operable gastrointestinal stromal tumor (GIST), but its influence on overall survival (OS) has remained uncertain.

Objective: To evaluate the effect of adjuvant imatinib on OS of patients who have a high estimated risk for GIST recurrence after macroscopically complete surgery.

Design, Setting, And Participants: In this open-label, randomized (1:1), multicenter phase 3 clinical trial conducted in Finland, Germany, Norway, and Sweden, 400 patients who had undergone macroscopically complete surgery for GIST with a high estimated risk for recurrence according to the modified National Institutes of Health Consensus Criteria were enrolled between February 2004 and September 2008. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2091DOI Listing

Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor.

Cells 2020 May 26;9(6). Epub 2020 May 26.

Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6:20, Karolinska University Hospital, SE-17164 Solna, Sweden.

Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST). However, the role of energy metabolism in imatinib-resistant GIST remains poorly characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9061333DOI Listing

Differential diagnosis of liver metastases of gastrointestinal stromal tumors from colorectal cancer based on combined tumor biomarker with features of conventional ultrasound and contrast-enhanced ultrasound.

Abdom Radiol (NY) 2020 May 26. Epub 2020 May 26.

Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, NO.58 Zhongshan Road 2, Guangzhou, 510080, People's Republic of China.

Purpose: To explore the value of tumor marker CA125 and CEA linked with conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) features in differentiating gastrointestinal stromal tumors liver metastases (GISTLM) from colorectal cancer liver metastases (CRCLM).

Materials And Methods: From December 2005 to February 2019, eighty patients with pathologically proven GISTLM together with 80 CRCLM patients were retrospectively evaluated with contrast-enhanced ultrasound (CEUS). Clinical characteristics such as CA125 and CEA were documented to compare the difference between GISTLM and CRCLM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02592-6DOI Listing

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.

Cancers (Basel) 2020 May 22;12(5). Epub 2020 May 22.

Medical Oncology Unit, University Hospital and University of Cagliari, 09042 Monserrato, Italy.

Background: In the last decade, a series of analyses failed to identify predictive biomarkers of resistance/susceptibility for anti-angiogenic drugs in metastatic colorectal cancer (mCRC). We conducted an exploratory preplanned analysis of serum pro-angiogenic factors (SErum aNgiogenesis-cenTRAL) in 72 mCRC patients enrolled in the phase II CENTRAL (ColorEctalavastiNTRiAlLdh) trial, with the aim to identify potential predictive factors for sensitivity/resistance to first line folinic acid-fluorouracil-irinotecan regimen (FOLFIRI) plus bevacizumab.

Methods: First-line FOLFIRI/bevacizumab patients were prospectively assessed for the following circulating pro-angiogenic factors, evaluated with ELISA (enzyme-linked immunosorbent assay)-based technique at baseline and at every cycle: Vascular endothelial growth factor A (VEGF-A), hepatocyte growth factor (HGF), stromal derived factor-1 (SDF-1), placental derived growth factor (PlGF), fibroblast growth factor-2 (FGF-2), monocyte chemotactic protein-3 (MCP-3), interleukin-8 (IL-8). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051330DOI Listing

Cabozantinib as an emerging treatment for sarcoma.

Curr Opin Oncol 2020 May 20. Epub 2020 May 20.

GINECO and Medical Oncology Department, Centre Léon Bérard, Université Claude Bernard Lyon, Lyon, France.

Purpose Of Review: Sarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease. Cabozantinib is a tyrosine kinase inhibitor currently approved for advanced renal cell, hepatocellular, and medullary thyroid carcinoma. Cabozantinib has potent activity against a variety of kinases, including MET, vascular endothelial growth factor receptor, and AXL, that are associated with sarcoma growth and development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000644DOI Listing

New drugs in gastrointestinal stromal tumors.

Curr Opin Oncol 2020 May 20. Epub 2020 May 20.

Institute of Biomedicine of Seville (HUVR CSIC.

Purpose Of Review: Tyrosine kinase inhibitors (TKIs) are the backbone for gastrointestinal stromal tumor (GIST) treatment. The increasing knowledge concerning the structure and the changing conformational status because of some mutations in KIT and PDGFRα, allowed the development of new efficient compounds, with the main goal to overcome resistance in GIST. This review summarizes the latest developments in the treatment of GIST patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000642DOI Listing

A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors.

Med Sci Monit 2020 May 25;26:e922378. Epub 2020 May 25.

Department of Gastroenterology, Affiliated Zhongshan Hospital of Fudan University, Shanghai, China (mainland).

BACKGROUND The aim of this study was to construct a nomogram to predict the prognosis of patients with gastrointestinal stromal tumor (GIST). MATERIAL AND METHODS We enrolled 4086 GIST patients listed in the SEER database from 1998 to 2015. They were separated to 2 groups: an experimental group (n=2862) and a verification group (n=1224). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.922378DOI Listing

Laparoscopic gastrectomy with lymph node dissection for the treatment of remnant stomach gastrointestinal stromal tumors in incomplete-type Carney's triad: a case report.

Surg Case Rep 2020 May 24;6(1):112. Epub 2020 May 24.

Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, 7-5-2 Kobeshi, Chuou-ku, Kusunoki-cho, Kobe, Hyogo, 650-0017, Japan.

Background: We report a rare case of gastrointestinal stromal tumors (GISTs) in Carney's triad, successfully treated using laparoscopic gastrectomy with lymph node dissection after chemotherapy.

Case Presentation: A 21-year-old woman presented to our hospital for treatment of recurrent GISTs. The patient had been admitted for treatment 11 years prior, with black stools being the chief presenting complaint at that time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-020-00877-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246277PMC

Comprehensive Review of Abdominopelvic Mesenchymal Tumors With Radiologic Pathologic Correlation and Update on Current Treatment Guidelines-Part 2.

Semin Ultrasound CT MR 2020 Apr 14;41(2):239-259. Epub 2020 Mar 14.

Department of Radiology and Orthopedics, University of Arkansas for Medical Sciences, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR.

Soft-tissue sarcomas are a diverse group of rare mesenchymal malignancies accounting for only 1% of all solid adult malignancies. These have been categorized in 12 broad groups by the World Health Organization (WHO) with their recent update in 2013. Majority of them lack specific imaging features serving as imaging conundrums for a radiologist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.sult.2020.03.003DOI Listing

Comprehensive Review of Abdominopelvic Mesenchymal Tumors with Radiologic Pathologic Correlation and Update on Current Treatment Guidelines - Part 1.

Semin Ultrasound CT MR 2020 Apr 15;41(2):222-238. Epub 2020 Feb 15.

Department of Radiology and Orthopedics, University of Arkansas for Medical Sciences, Little Rock, AR.

Soft-tissue sarcomas are a diverse group of rare mesenchymal malignancies accounting for only 1% of all solid adult malignancies. These have been categorized in 12 broad groups by the World Health Organization (WHO) with their recent update in 2013. Majority of them lack specific imaging features serving as imaging conundrums for a radiologist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.sult.2020.01.002DOI Listing

Clinicopathologic and Surgical Characteristics Study of 151 Cases of GIST.

J Gastrointest Cancer 2020 May 22. Epub 2020 May 22.

Department of General Surgery, Necmettin Erbakan University Meram Medicine Faculty, Konya, Turkey.

Background: Gastrointestinal stromal tumor (GIST) is the most appearing mesenchymal tumor of the gastrointestinal system. In this study, we are aiming to share the most up to date knowledge about diagnosis and treatment of these tumors by transferring our clinical experience about GISTs.

Methods: The 151 patients who were operated between 2006-2020 and whose pathological examination was reported as GIST were analyzed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-020-00414-yDOI Listing

Difference in Perfusion Parameters Between Gastric Cancer and Gastric Stromal Tumors: Evaluation With Oral Contrast Plus Contrast-Enhanced Ultrasonography.

Front Oncol 2020 5;10:532. Epub 2020 May 5.

Department of Ultrasound, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

To explore the difference of perfusion parameters between gastric cancer (GC) and gastric stromal tumors (GSTs) by using oral contrast plus contrast-enhanced ultrasonography (OC+CEUS). We retrospectively reviewed 149 patients with histologically confirmed gastric lesions (80 patients with GC and 69 patients with GST). OC+CEUS was performed in all patients in the GC group and the GST group before surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00532DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214801PMC

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.

Eur J Clin Pharmacol 2020 May 19. Epub 2020 May 19.

Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

Purpose: The aim of this study was to ascertain whether the absolute bioavailability of oral imatinib (Glivec®) during steady state plasma pharmacokinetics in cancer patients could be determined through a concomitant intravenous administration of a single 100 μg microdose of deuterium labeled imatinib (imatinib-d8). Secondly, the usefulness of liquid chromatography-tandem mass spectrometry (LC-MS/MS) was investigated for simultaneous analysis of orally and intravenously administered imatinib.

Methods: Included patients were on a stable daily dose of 400 mg oral imatinib prior to study participation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-020-02888-yDOI Listing

Comparison of endoscopic versus laparoscopic resection for gastric gastrointestinal stromal tumors: a preliminary meta-analysis.

J Gastroenterol Hepatol 2020 May 19. Epub 2020 May 19.

Medical Centre for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Background And Aim: For localized disease, complete surgical resection is regarded as the "Gold Standard" therapeutic modality. With the rapid development of endoscopic techniques, endoscopic resection (ESR) has been confirmed as an efficient and safe alternative for the treatment of gastrointestinal stromal tumors (GISTs) in the stomach. Nevertheless, the management of gastric GISTs remains poorly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.15106DOI Listing

Clinical course of suspected small gastrointestinal stromal tumors in the stomach.

World J Gastrointest Surg 2020 Apr;12(4):171-177

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

Background: Gastric subepithelial lesions are frequently encountered during endoscopic examinations, and the majority of them are small and asymptomatic. Among these lesions, gastrointestinal stromal tumors (GISTs) are the major concern for patients and clinicians owing to their malignant potentials. Although previous guidelines suggested periodic surveillance for such small (≤ 20 mm) lesions, several patients and clinicians have still requested or prescribed repeated examinations or radical resection, posing extra medical burdens and risks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4240/wjgs.v12.i4.171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215971PMC

Synchronous Periampullary Tumors in a Patient With Pancreas Divisum and Neurofibromatosis Type 1.

Front Genet 2020 28;11:395. Epub 2020 Apr 28.

Laboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Introduction: In this study, we describe for the first time a Neurofibromatosis type 1 patient with pancreas divisum, multiple periampullary tumors and germline pathogenic variants in and genes.

Case Report: A 62-year-old female NF1 patient presented with weakness, choluria, nausea, and diffuse abdominal pain to an emergency room service. Magnetic resonance imaging revealed an abdominal mass involving the periampullary region and pancreas divisum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2020.00395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212385PMC

Matrine reduces the secretion of exosomal circSLC7A6 from cancer-associated fibroblast to inhibit tumorigenesis of colorectal cancer by regulating CXCR5.

Biochem Biophys Res Commun 2020 Jun 15;527(3):638-645. Epub 2020 May 15.

Department of Gastrointestinal Surgery, Suzhou Ninth People's Hospital, Suzhou, China. Electronic address:

Tumor microenvironment (e.g., stromal cells) has been suggested to be implicated in colorectal cancer (CRC) progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2020.04.142DOI Listing

[Jejunal gastrointestinal stromal tumor (GIST): clinical case].

Rev Med Inst Mex Seguro Soc 2020 Jan 1;58(1):66-75. Epub 2020 Jan 1.

Instituto Mexicano del Seguro Social, Hospital General de Zona No. 23, Servicio de Cirugía General. Hidalgo del Parral, Chihuahua, México.

Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. It is exposed a clinical case of jejunal GIST from a second-level hospital in Mexico.

Clinical Case: Female patient of 76 years, with history of tobacco use (two cigarettes per day for 25 years), that is referred to General Surgery due to a four month evolution of symptoms, characterized by abdominal pain, hyporexia and urinary symptomatology. Read More

View Article

Download full-text PDF

Source
January 2020

Establishment and Verification of Synchronous Metastatic Nomogram for Gastrointestinal Stromal Tumors (GISTs): A Population-Based Analysis.

Gastroenterol Res Pract 2020 27;2020:8493707. Epub 2020 Jan 27.

Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China.

Aim: Assess the risk of synchronous metastasis and establish a nomogram in patients with GISTs.

Methods: Surveillance, Epidemiology and End Results database (2004-2014) was accessed. With the logistic regression model as the basis, a nomogram was constructed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/8493707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204200PMC
January 2020

Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success.

Sci Rep 2020 May 14;10(1):7996. Epub 2020 May 14.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Patient-derived xenografts (PDXs) can represent the heterogeneity and histological characteristics of tumors and are thus useful for testing the efficacy of anti-cancer drugs; however, PDXs are difficult to generate, especially for gastrointestinal stromal tumor (GIST). We analyzed the clinicopathologic factors associated with the successful establishment of GIST PDX in NOD.Cg-Prkdc IL2rg/SzJ mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-64552-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224375PMC

Clinicopathologic characteristics, diagnostic clues, and prognoses of patients with multiple sporadic gastrointestinal stromal tumors: a case series and review of the literature.

Diagn Pathol 2020 May 14;15(1):56. Epub 2020 May 14.

Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Road, Shanghai, 200127, People's Republic of China.

Background: Most sporadic gastrointestinal stromal tumors (GISTs) occur as solitary tumors, while multiple sporadic GISTs are extremely rare and often misdiagnosed as metastatic GISTs, leading to inappropriate treatment. This study aimed to investigate the clinicopathological characteristics, diagnostic clues, and prognoses of multiple sporadic GISTs.

Methods: Twenty-seven patients with multiple sporadic GISTs and 11 patients with metastatic GISTs mimicking sporadic GISTs were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-020-00939-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222320PMC

Endoscopic ultrasound-guided fine-needle aspiration cytology in the diagnosis of the gastrointestinal stromal tumor of the stomach.

Diagn Cytopathol 2020 May 13. Epub 2020 May 13.

Anatomical Pathology Service, Marqués de Valdecilla University Hospital, University of Cantabria and IDIVAL Research Institute, Santander, Spain.

Background: This study aims to evaluate the usefulness of endoscopic ultrasound-guided fine-needle aspiration cytology (EUS-FNAC) in the diagnosis of the gastric gastrointestinal stromal tumor (GIST).

Methods: We retrospectively investigated the efficacy and accuracy of EUS-FNAC in the diagnosis of gastric GIST. Cytological smears and cytoblock sections including immunohistochemistry and mutational studies from patients diagnosed as gastric GISTs were retrieved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24442DOI Listing

Modified endoscopic full-thickness resection of gastric stromal tumor originating from the muscularis propria layer.

J Gastrointest Oncol 2020 Apr;11(2):461-466

Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing 400030, China.

Endoscopic full-thickness resection (EFTR) is emerging as an approach to resect gastric gastrointestinal stromal tumors originating from the muscularis propria layer (MP-GISTs) because several established endoscopic closure methods and tools have been developed. However, EFTR is performed difficultly due to three challenges: limited luminal insufflation and visualization, insufficient operating space, and inadequate exposure of cutting line. Therefore, we performed a novel method of clip- and snare-assisted EFTR (also named as m-EFTR or chen-EFTR) to resect a MP-GIST. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2020.03.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212117PMC

Which size is the best cutoff for primary small gastric gastrointestinal stromal tumor?

J Gastrointest Oncol 2020 Apr;11(2):402-410

Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510000, China.

Background: The biological behavior of primary small gastric gastrointestinal stromal tumor (gGIST) is indolent. The cutoff size categorizing small gGIST continues to be controversial. To date, there is no consensus regarding whether it should be 1 cm, 2 cm, or another size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2020.03.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212102PMC

The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor.

Int J Mol Sci 2020 May 7;21(9). Epub 2020 May 7.

Medical Oncology Unit, S.Orsola-Malpighi University Hospital, 40138 Bologna, Italy.

Gastrointestinal stromal tumors (GIST) are rare neoplasms of mesenchymal origin arising in the gastrointestinal tract. The vast majority are characterized by mutually exclusive activating mutations in KIT or Platelet-derived growth factor alpha (PDGFRA) receptors, or less frequently by succinate dehydrogenase complex (SDH) or NF1 inactivation, with very rare cases harboring mutant BRAF or RAS alleles. Approximately 5% of GISTs lack any of such mutations and are called wild-type (WT) GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21093313DOI Listing

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST.

Front Oncol 2020 22;10:504. Epub 2020 Apr 22.

"Giorgio Prodi" Cancer Research Center, University of Bologna, Bologna, Italy.

Gastrointestinal stromal tumors (GIST) are known to carry oncogenic KIT or PDGFRA mutations, or less commonly SDH or NF1 gene inactivation, with very rare cases harboring mutant BRAF or RAS alleles. Approximately 10% of GISTs are devoid of any of such mutations and are characterized by very limited therapeutic opportunities and poor response to standard treatments. Twenty-six sporadic KIT/PDGFRA/SDH/RAS-pathway wild type GIST were profiled for the molecular status of genes frequently altered in GIST by a targeted next generation sequencing (NGS) approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188756PMC

A rare case of jejunal gastrointestinal stromal tumor.

Ann Ital Chir 2019 Dec 20;8. Epub 2019 Dec 20.

Gastrointestinal stromal tumors(GISTs) are rare neoplasms of the gastrointestinal(GI) system originating from the mesenchyme. GISTs mostly develop in the stomach and small intestine. We present here a case of jejunal GIST which is the rarest subtype. Read More

View Article

Download full-text PDF

Source
December 2019

Morphological features useful in the differential diagnosis between undifferentiated carcinoma and gastrointestinal stromal tumor.

Ann Diagn Pathol 2020 May 3;46:151527. Epub 2020 May 3.

Sikl's Institute of Pathology, Faculty of Medicine and Teaching Hospital in Plzen, Charles University, Plzen, Czech Republic; Bioptical Laboratory, Ltd., Plzen, Czech Republic. Electronic address:

Undifferentiated (sarcomatoid) carcinomas may closely mimic gastrointestinal stromal tumors (GISTs) due to possible histological and immunohistochemical overlap between these two entities. To avoid unnecessary employment of a wide spectrum of immunohistochemical stainings and molecular genetics and thus decrease costs, finding simple morphological features to target further investigation of such neoplasms of the gastrointestinal tract would be helpful. Five cases classified as undifferentiated (sarcomatoid) carcinomas with a definite proof of the diagnosis, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2020.151527DOI Listing

Circulating tumor cells in whole process management of gastrointestinal stromal tumor in a real-life setting.

Saudi J Gastroenterol 2020 May-Jun;26(3):160-167

Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China.

Background/aim: Liquid biopsy is changing the diagnosis and treatment strategies of various neoplasms. However, the circulating tumor cells (CTCs) of gastrointestinal stromal tumor (GIST) patients with different disease process are not clear. To better understand the dynamic change of CTCs in GIST patients, we conducted a real-life setting study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sjg.SJG_24_20DOI Listing

Hepatic nodules with arterial phase hyperenhancement and washout on enhanced computed tomography/magnetic resonance imaging: how to avoid pitfalls.

Abdom Radiol (NY) 2020 May 6. Epub 2020 May 6.

Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhong Shan Road 2, Guangzhou, 510080, China.

This essay aimed to illustrate the various hepatic nodules that may exhibit arterial phase hyperenhancement and washout on computed tomography/magnetic resonance imaging (CT/MRI). Hepatic nodules with arterial phase hyperenhancement and washout on CT/MRI include hepatocellular carcinoma, focal nodular hyperplasia-like nodules, serum amyloid A-positive hepatocellular neoplasms, intrahepatic cholangiocarcinoma, intrahepatic bile duct adenoma, hepatoblastoma, hepatocellular adenoma, hepatic epithelioid angiomyolipoma, and metastasis including neuroendocrine and gastrointestinal stromal tumors. Understanding the imaging findings is important to ensure correct diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02560-0DOI Listing

Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study.

World J Surg Oncol 2020 May 6;18(1):88. Epub 2020 May 6.

Institute of Digestive Surgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

Background: To explore overall survival (OS) and GISTs-specific survival (GSS) among cancer survivors developing a second primary gastrointestinal stromal tumors (GISTs).

Methods: We conducted a cohort study, where patients with GISTs after another malignancy (AM-GISTs, n = 851) and those with only GISTs (GISTs-1, n = 7660) were identified from the Surveillance, Epidemiology, and End Results registries (1988-2016). Clinicopathologic characteristics and survival were compared between the two groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12957-020-01868-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204066PMC

Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.

Front Oncol 2020 21;10:536. Epub 2020 Apr 21.

Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Comprehensive Genomic Profiling may be informative for novel treatment strategies and to improve outcomes for patients with rare tumors. This study aims to discover opportunities for use of targeted therapies already approved for routine use in patients with rare tumors. Solid tumors with an incidence lower than 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186305PMC

Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors.

J Clin Med 2020 May 1;9(5). Epub 2020 May 1.

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9051301DOI Listing

Invited Commentary on "Radical excision versus local resection for primary rectal gastrointestinal stromal tumors. A cohort study" (Int J Surg 2020; 77:190-197).

Int J Surg 2020 Apr 29;78:145-146. Epub 2020 Apr 29.

Department of Surgery, University of Michigan, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijsu.2020.04.053DOI Listing

ALK rearrangement in a gastrointestinal stromal tumor of the small bowel.

Histopathology 2020 May 1. Epub 2020 May 1.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

The most common drivers of gastrointestinal stromal tumors (GIST) are oncogenic activating mutations in KIT (75%) or PDGFRA (10%) [1]; 5% of GISTs are succinate dehydrogenase (SDH)-deficient, secondary to either SDHx mutations or SDHC promoter hypermethylation [2]. Rare GISTs have alternate drivers, including BRAF, RAS, or NF1 mutations, or NTRK3 or FGFR1 fusions. Here we report the first case of GIST with an ALK gene rearrangement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14133DOI Listing

Significance of Primary Malignant Tumors on the Outcome of Patients With Resected Gastrointestinal Stromal Tumors.

In Vivo 2020 May-Jun;34(3):1201-1205

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Aim: This study aimed to clarify the significance of primary malignant tumors for the outcome of resected gastrointestinal stromal tumors (GISTs).

Patients And Methods: The medical history, pathological findings and prognosis of 66 patients with GISTs resected at our institute between January 2003 and December 2018 were investigated retrospectively and compared statistically.

Results: Among 66 patients with GISTs, 24 (36%) had concomitant malignant tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.11893DOI Listing
February 2020

Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors.

Clin Transl Gastroenterol 2020 Mar;11(3):e00156

Department of Gastroenterology, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China.

Objectives: The diagnostic value of different noninvasive diagnostic modalities and the endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) reliability of duodenal gastrointestinal stromal tumors (GISTs) are ambiguous in the present studies.

Methods: Patients with a histopathological diagnosis of the primary duodenal GISTs between the years 2008 and 2018 were analyzed. Data on the treatment and clinicopathological features were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ctg.0000000000000156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145047PMC

Theranostic Gastrointestinal Endoscopy: Bringing Healing Light to the Lumen.

Clin Transl Gastroenterol 2020 Mar;11(3):e00119

Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

Current conventional endoscopes have restricted the accuracy of treatment delivery and monitoring. Over the past decade, there have been major developments in nanotechnology and light triggered therapy, potentially allowing a better detection of challenging lesions and targeted treatment of malignancies in the gastrointestinal tract. Theranostics is a developing form of personalized medicine because it combines diagnosis and targeted treatment delivered in one step using advances in nanotechnology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ctg.0000000000000119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145051PMC

Recent Anti-platelet Therapy Revealing Underlying Undiagnosed Gastrointestinal Stromal Tumor in Otherwise Healthy Patient.

Cureus 2020 Mar 28;12(3):e7450. Epub 2020 Mar 28.

Gastroenterology, BronxCare Health System, Bronx, USA.

Gastrointestinal stromal tumors (GIST) are uncommon tumors of the gastrointestinal (GI) tract that arise from primitive mesenchymal cells. Usually, GIST presents as chronic gastrointestinal symptoms or obscure gastrointestinal bleed. Not many cases have been reported in the literature with acute symptoms in the setting of recent aspirin use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186083PMC

Diagnostic value of contrast-enhanced harmonic endoscopic ultrasonography in predicting the malignancy potential of submucosal tumors: a systematic review and meta-analysis.

Surg Endosc 2020 Apr 29. Epub 2020 Apr 29.

Department of Gastroenterology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, People's Republic of China.

Objectives: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) utilizes the second-harmonic signals from contrast microbubbles located in the vessels to improve the detectability of microcirculation. Many studies have used CH-EUS to stratify the malignancy risk of submucosal tumors (SMTs), discriminate gastrointestinal stromal tumors (GISTs) from benign SMTs, and predict the malignancy of GISTs based on the regularity of vessels or enhancing patterns. The aim of this study was to conduct a meta-analysis to evaluate the diagnostic performance of CH-EUS in the differential diagnosis of SMTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00464-020-07585-6DOI Listing

Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.

Mod Pathol 2020 Apr 29. Epub 2020 Apr 29.

Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.

Glucocorticoid-induced TNF receptor (GITR) is an emerging immunotherapy target that is expressed at high levels on regulatory T cells. Agonistic anti-GITR antibodies have anti-tumor activity in cancer mouse models, and recent phase 1 trials have demonstrated their safe pharmacological profile. However, there is limited knowledge on the relationship between GITR expression and the tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0550-zDOI Listing

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.

Sci Transl Med 2020 Apr;12(541)

Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA.

Gastrointestinal stromal tumor (GIST) is the most common human sarcoma driven by mutations in or platelet-derived growth factor α (α). Although first-line treatment, imatinib, has revolutionized GIST treatment, drug resistance due to acquisition of secondary /α mutations develops in a majority of patients. Second- and third-line treatments, sunitinib and regorafenib, lack activity against a plethora of mutations in KIT/PDGFRα in GIST, with median time to disease progression of 4 to 6 months and inhibition of vascular endothelial growth factor receptor 2 (VEGFR2) causing high-grade hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaz2481DOI Listing

Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel.

Diagnostics (Basel) 2020 Apr 23;10(4). Epub 2020 Apr 23.

Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), Molecular Diagnostic Unit, University of Bologna, Azienda USL di Bologna, viale Ercolani 4/2, 40138 Bologna, Italy.

Next generation sequencing (NGS) allows parallel sequencing of multiple genes at a very high depth of coverage. The need to analyze a variety of targets for diagnostic/prognostic/predictive purposes requires multi-gene characterization. Multi-gene panels are becoming standard approaches for the molecular analysis of solid lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10040250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236002PMC